Regulatory and Clinical Development Strategy for Peptides in the Era of ICH; Oligonucleotide Products – Comparing the Regulatory Environment in US and China

Posted by

Join us at

AsiaTIDES: Oligonucleotide & Peptide Therapeutics

February 26-28, 2019 | Hilton Tokyo Bay Hotel |Tokyo, Japan

Dan Zhang

Dan Zhang, PhD

Co-Founder & CEO Fountain Medical Development

an illustration of combined regulatory and clinical development strategies for peptides among ICH countries by taking advantage of new ICH guidelines such as E17 MRCT guideline. It will also compare the regulatory environment for oligonucleotides in the US and China.